Pharmaron Beijing Co., Ltd.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
5/10
|
31.82 | 69.4 | -54.15% | 358.34 | -91.12% |
| P/S |
|
4.31 | 6.51 | -33.76% |
|
|
| P/BV |
|
4.3 | 3.96 | 8.69% |
|
|
| P/FCF |
|
0 | 0 | 0% |
|
|
| Ev/Ebitda |
|
24.23 | 11.85 | 104.5% |
|
|
| Ev/S |
|
4.34 | 5.98 | -27.33% |
|
|
| Ev/FCF |
|
0 | 0 | 0% |
|
|
| E/P |
|
0.0337 | 0.0396 | -14.89% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
5/10
|
16.15 | 16.34 | -1.17% | 28.52 | -43.37% |
| ROE |
|
13.56 | 11.95 | 13.51% |
|
|
| ROA |
|
5.54 | 5.4 | 2.56% |
|
|
| ROIC |
|
0 | 0 | 0% |
|
|
| ROS |
|
13.5 | 16.23 | -16.83% |
|
|
| ROCE |
|
0 | 0 | 0% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
5/10
|
2.62 | 14.63 | -82.11% | 2.09 | +25.05% |
| Nеt Debt/Ebitda |
|
0 | 0 | 0% |
|
|
| Debt/Ratio |
|
0 | 0 | 0% |
|
|
| Debt/Equity |
|
0 | 0 | 0% |
|
|
| Debt/Net Income |
|
4.18 | 3.6 | 16.21% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
2.48/10
|
0.99 | 1.83 | -45.99% | 0.2389 | +314.41% |
| Number of years of dividend growth |
|
0 | 1.44 | -100% | ||
| DSI |
|
1 | 0.9113 | 9.73% |
|
|
| Average dividend growth |
|
33.06 | 10.4 | 217.99% |
|
|
| Average percentage for 5 years |
|
0.2389 | 1.14 | -79.08% |
|
|
| Average percentage for payments |
|
21.06 | 44.8 | -52.99% |
|
|
| Difference from average difference in sector |
|
-0.843 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
10/10
|
207.09 | 61.43 | 237.12% | ||
| Growth impulse Ebitda in 5 years |
|
269.96 | 158.62 | 70.19% | ||
| Growth impulse Net Income in 5 years |
|
192.6 | 66.93 | 187.76% | ||
| Growth impulse FCF in 5 years |
|
-160.76 | 248.41 | -164.72% | ||
| Growth impulse EPS in 5 years |
|
35.11 | 73.29 | -52.09% |
IP Score
5.59/10
